Cimzia is indicated for the treatment of4:
- Moderate to severe, active rheumatoid arthritis (RA) in adult patients when the response to disease-modifying antirheumatic drugs (DMARDs) including MTX, has been inadequate. Cimzia can be given as monotherapy in case of intolerance to MTX or when continued treatment with MTX is inappropriate.
- Severe, active and progressive RA in adults not previously treated with MTX or other DMARDs.
- Adults with severe active ankylosing spondylitis who have had an inadequate response to, or are intolerant to nonsteroidal anti-inflammatory drugs (NSAIDs).
- Adults with severe active axial spondyloarthritis without radiographic evidence of AS but with objective signs of inflammation by elevated C-reactive protein (CRP) and /or magnetic resonance imaging (MRI), who have had an inadequate response to, or are intolerant to NSAIDs.
- Active psoriatic arthritis in adults when the response to previous DMARD therapy has been inadequate. Cimzia can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate.
- Moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.
The use of adequate contraception should be considered for women of childbearing potential who have been prescribed Cimzia. For women planning pregnancy, continued contraception may be considered for 5 months after the last Cimzia dose due to its elimination rate. Cimzia should only be used during pregnancy if clinically needed.4
Please refer to the SmPC for further information.